Anticoagulation and hemostasis on extracorporeal membrane oxygenation : Current Opinion in Pediatrics

Secondary Logo

Journal Logo

EMERGENCY AND CRITICAL CARE MEDICINE: Edited by Jean E Klig and Clifford W Bogue

Anticoagulation and hemostasis on extracorporeal membrane oxygenation

Carmona, Carlosa; Nellis, Marianne E.b; Karam, Oliverc

Author Information
Current Opinion in Pediatrics 35(3):p 297-302, June 2023. | DOI: 10.1097/MOP.0000000000001247


Purpose of review 

The purpose of this review is to describe the hemostatic changes induced by extracorporeal membrane oxygenation (ECMO), the need to balance the risks of bleeding and clotting with anticoagulation and hemostatic transfusions, and the inherent risks to these interventions.

Recent findings 

Both bleeding and clotting are frequent complications of ECMO. To prevent clotting events, virtually, all children are anticoagulated. However, the optimal anticoagulation strategy is unknown. A recent systematic review of observational studies showed that anti-Xa-guided strategies were associated with a two-fold decrease in bleeding and no increase in clotting complications. These results need to be tested in randomized controlled trials. To avoid bleeding events, platelet transfusions are frequently prescribed to children on ECMO. However, platelet transfusions have recently been shown to be independently associated with increased bleeding and clotting. Therefore, the optimal platelet transfusion strategy must be evaluated appropriately.


Most patients on ECMO will develop either a hemorrhagic or thrombotic complication. Balancing these risks involves careful titration of anticoagulation to prevent clotting and hemostatic transfusions to prevent bleeding. As the current level of evidence is low, prospective randomized trials are needed.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid